The New Era of Rare Disease Drug Development: Trends to Watch
17 June 2026 Category: Drug DevelopmentHere is a number that should stop you: more than 10,000 rare diseases have been identified globally, yet fewer than 500 have an approved treatment.
Here is a number that should stop you: more than 10,000 rare diseases have been identified globally, yet fewer than 500 have an approved treatment.
This is why more pharmaceutical companies are investing in unified intelligence platforms that centralize data, improve visibility, and support better decision-making across the drug development lifecycle.
Discover how early-phase pipeline tracking helps pharmaceutical companies identify high-value licensing opportunities, assess risks, and gain competitive advantage.
Backed by latest FDA data, this article analyzes approval trends, clinical challenges, and innovation drivers in pharmaceutical R&D.
Oncology is printing money. There is no other therapy area in global pharma that even comes close to the numbers being put up by cancer drugs right now.
This post isn't about defining what pipeline intelligence is. It's about what it does, specifically, the seven strategic advantages it gives pharma manufacturers who choose to act on it rather than admire it from a distance.
India makes a lot of medicine. A LOT. It ships pills, syrups, and injections to more than 200 countries.
Data is no longer optional. It is the engine of modern drug development. The question is whether your organization is driving it, or being left behind by it.
Biologic medicines changed modern healthcare. They treat complex diseases like cancer, autoimmune disorders, and diabetes.
Pharma R&D waste is often mistaken for scientific failure. In reality, a large portion of it is strategic and preventable.